

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7200420

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DR. CARL WEINER	03/01/2022
DR. YAFENG DONG	03/01/2022
RECEIVING PARTY DATA	
Name:	ROSETTA SIGNALING LABORATORIES, LLC
Street Address:	5735 E. ORANGE BLOSSOM LN
City:	PHOENIZ
State/Country:	ARIZONA
Postal Code:	85018-6728
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	15991725
Application Number:	17118322
Application Number:	17203534
CORRESPONDENCE DATA	
Fax Number:	(435)252-1361
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	435-252-1360
Email:	agibbs@mabr.com
Correspondent Name:	JONATHAN M. BENNS
Address Line 1:	1389 CENTER DRIVE, SUITE 300
Address Line 4:	PARK CITY, UTAH 84098
ATTORNEY DOCKET NUMBER:	W2460.0
NAME OF SUBMITTER:	JONATHAN M. BENNS
SIGNATURE:	/Jonathan M. Benns/
DATE SIGNED:	03/01/2022
Total Attachments: 6	
source=Rosetta Assignment- signed Mar 1 2022#page1.tif	
source=Rosetta Assignment- signed Mar 1 2022#page2.tif	
source=Rosetta Assignment- signed Mar 1 2022#page3.tif	

source=Rosetta Assignment- signed Mar 1 2022#page4.tif

source=Rosetta Assignment- signed Mar 1 2022#page5.tif

source=Rosetta Assignment- signed Mar 1 2022#page6.tif

ASSIGNMENT

This Assignment is dated and made effective as of 3-1-2022 (the "Effective Date"), and is by and between Rosetta Signaling Laboratories, LLC, a Kansas limited liability company, having a place of business at 5735 E. Orange Blossom LN, Phoenix, AZ, U.S.A., including any present or future affiliates, related parties, successors and/or assigns of Rosetta Signaling Laboratories, LLC (collectively "ROSETTA") and DR. CARL WEINER, an individual ("Member"), and DR. YAFENG DONG, an individual ("Member"), has made certain new and useful inventions and improvements for which we executed an application for Letters Patent (the "Technology") of the United States and any and all other foreign countries which are listed on Appendix A, attached hereto.

AND WHEREAS, Rosetta Signaling Laboratories, LLC, a Kansas limited liability company, having a place of business at 5735 E. Orange Blossom LN, Phoenix, AZ, U.S.A. (hereinafter 'ROSETTA'), desires to acquire the entire right, title and interest in and to any and all inventions, improvements, copyrights, and/or contributions by Member(s) to the Technology listed on Appendix A;

NOW, THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, the parties agree as follows:

1. Assignment: We, the Member(s), have assigned, and transferred, and by these presents do assign and transfer unto ROSETTA, its successors or assigns, the entire right, title and interest for all countries in and to all inventions and improvements disclosed in the aforesaid inventions, applications and Letters of Patent to the Technology, and in and to the said application, all divisions, continuations, continuations-in-part, or renewals thereof, Letters of Patent which may be granted there from, and all reissues or extensions of such patents, and in and to any and all applications which have been or shall be filed in any foreign countries for the Technology on the said inventions and improvements, including an assignment of all rights under the provisions of the International Convention, and all the Letters of Patent of foreign countries which may be granted there from; and we do hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all United States Letters Patent for the aforesaid inventions and improvements to ROSETTA as the assignee of the entire right, title and interest in and to the same, for the use of ROSETTA, its successors and assigns.

2. Cooperation: WHEREAS, the Member(s) have a relationship with ROSETTA as initial members and founders; ROSETTA desires to continue Members services for the development design, testing and/or consulting regarding products, component, compounds, formulations, and/or procedures using or related to the propriety ROSETTA technology or designs, or proprietary third-party technology acquired by ROSETTA (collectively the "Technology"), or for the provision of services related thereto.

3. Counterparts: This Assignment may be executed in counterparts, each of which will be an original as regards any party whose signature appears thereon and both of which together will constitute one and the same instrument.

AND, for the consideration aforesaid, Member(s) do hereby agree that we and our executors and legal representatives will make, execute and deliver any and all other instruments in writing

including any and all further application papers, affidavits, assignments and other documents, and will communicate to ROSETTA, its successors and representatives all facts known to the Member(s) relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in ROSETTA, its successors or assigns the entire right, title and interest in and to the said improvements, inventions, applications, Letters Patent, rights, titles, benefits, privileges and advantages to the Technology hereby assigned and conveyed, or intended so to be.

AND, furthermore, Member(s) covenant and agree with ROSETTA, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the Member(s) and that full right to convey the same as herein expressed is possessed by us.

IN TESTIMONY WHEREOF, I have executed this Assignment as of the day and year first written above.

Dr. Carl Weiner ("Member")

By: 

Printed Name: Carl Weiner

IN TESTIMONY WHEREOF, I have executed this Assignment as of the day and year first written above.

Dr. Yafeng Dong ("Member")

By: 

Printed Name: Yafeng Dong

APPENDIX A					
Country	App No.	Filing Date	Title	Patent No.	Issue Date
US	15/991,725	2018-05-29	COMBINATIONS OF CELL FREE NUCLEIC ACIDS	10,954,564	2021-03-23
US	17/118,322	2020-12-10	COMBINATIONS OF CELL FREE NUCLEIC ACIDS		
EP	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
AT	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
BE	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
FR	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
DE	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
IE	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
IT	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
NL	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
ES	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
CH	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS	2646554	2016-06-08

			PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD		
GB	11845889.2	2011-11-30	PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD	2646554	2016-06-08
US	17/203,534	2021-03-16	COMBINATIONS OF BIOMARKERS FOR METHODS FOR DETECTING TRISOMY 21		